Antisense Therapeutics Limited (ASX:ANP)


right-arrow Created with Sketch. 0 (0%)
MCAP $131.5M
Last trade 16.10pm 26/11/2021 20mins delayed

Latest Announcements

23/11/2021ANPAntisense Therapeutics Limited
23/11/2021ANPAntisense Therapeutics Limited
15/11/2021ANPAntisense Therapeutics Limited
11/11/2021ANPAntisense Therapeutics Limited
08/11/2021ANPAntisense Therapeutics Limited
05/11/2021 Price SensitivePSANPAntisense Therapeutics Limited
05/11/2021ANPAntisense Therapeutics Limited
05/11/2021ANPAntisense Therapeutics Limited

Company Overview

Antisense Therapeutics Limited is an Australia-based biotechnology company. The Company is engaged in developing and commercializing antisense pharmaceuticals for unmet markets in rare diseases. The Company's product candidate, ATL1103, is an antisense drug designed to block growth hormone receptor (GHr) expression thereby reducing levels of the hormone insulin-like growth factor-I (IGF-I) in the blood. ATL1103 is in clinical development for acromegaly. The Company's product candidate, ATL1102, is an antisense inhibitor targeting very late antigen 4 (VLA-4), an immune cell molecule. The Company completed a Phase IIa efficacy and safety trial of ATL1102 in multiple sclerosis (MS) patients. The Company is engaged in clinical development of ATL1102 in patients with Duchenne Muscular Dystrophy (DMD). The Company is conducting a Phase II clinical trial of ATL1102 in DMD patients.

ANP in the news

The Paediatric Committee (PDCO) of the European Medicines Agency (EMA) has given…
Antisense Therapeutics (ANP) says it has received positive feedback received on the…
Antisense Therapeutics (ANP) has presented new data to support its ATL1102 drug…
Antisense Therapeutics (ANP) announces its new proteomics data will be presented in…

Search Previous Announcements